DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

By N. Ferrara, L. Damico, Naveed B. K. Shams, H. Lowman, R. Kim. Retina, 2006

877 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/574dc5afee9b071675a34ef485360a4f5a266747

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. D. Hanahan

In Molecular Biology

1. D. Hanahan
2. G. Bergers
3. A. Adamis
4. Rakesh K. Jain
5. N. Ferrara
6. R. Weinberg
7. J. Joyce
8. Peter Carmeliet

In Ophthalmology

1. A. Adamis
2. D. Boyer
3. D. Hanahan
4. David M. Brown
5. N. Ferrara

Citations in the corpus

• Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. (2013, background): “In contrast, Folkman’s pioneering work in angiogenesis led to the discovery of precise molecular mechanisms that could be specifically targeted in cancer, macular degeneration, and diabetic retinopathy (DR).2 The subsequent cloning of vascular endothelial growth factor 2013 by the American Academy o”
• Modes of resistance to anti-angiogenic therapy (2008, background): “Moreover, two VEGF pathway inhibitors (the RNA aptamer pegaptanib and a Fab derivative of bevacizumab) have been approved for treating the angiogenic (wet) form of macular degeneratio”